The results indicated that the use of PD-1/PD-L1 inhibitors increases the risk of all-grade rash, pruritus, colitis, elevated AST, hypothyroidism, hyperthyroidism, as well as both all-grade and high-grade pneumonitis (Nishijima et al., 2017). Here, CD274 is linked to hypothyroidism.